MeSH D016908 - gram-positive bacterial infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D001424:Bacterial infections
D016908:
Gram-positive bacterial infections
D000193:Actinomycetales infections
D003015:Clostridium infections
D004889:Erysipelothrix infections
D008088:Listeriosis
D013203:Staphylococcal infections
D013290:Streptococcal infections
D016863:Bacillaceae infections
0 Companies
0 Drugs
Success rate
D039941:Bifidobacteriales infections
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Merck Sharp & Dohme | Daptomycin | Cubicin | 2006-01-19 | $152 M | Y2020 |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
11%1/9
Phase 2
75%6/8
Phase 3
58%14/24
Approved: 10Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use